Back to top

Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. Joseph Pantgi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Esperion Therapeutics, Inc. (ESPR)